Receive a copy of our current research models and services product guide.
Target Sufficiency® enables direct, quantitative analysis of drug target systems in cells, biofluids, tissues, and tissue models, including formalin-fixed, paraffin-embedded (FFPE) tissues.
Reduce costs with our complimentary sample for evaluation in your lab.
Inotiv delivers a broad array of nonclinical and analytical services from discovery through clinical development.
Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
July 22, 2024 | 11:00am EDT Presented by: Dr. Jessica Ramadhin – Field Applications Scientist, Taconic Biosciences,
July 24, 2024 | 2:00pm EDT Presented by: Dr. Melissa M. Walker, Associate Director of Pharmacology – Gastrointestinal Inflammation,
September 8-11, 2024 Copenhagen, Denmark Booth #15 EUROTOX is the Federation of European Toxicologists and European Societies of Toxicology, which tog...
July 25, 2024 WEST LAFAYETTE, Ind., July 25, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”),&...
June 10, 2024 WEST LAFAYETTE, Ind., June 10, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”),
Company reaffirms commitment to maintaining appropriate standards of animal welfare June 3, 2024 WEST LAFAYETTE, Ind., June 03, 2024 (GLOBE NEWSWIRE) -- Inotiv Inc. – ...
How Differences Between Experimental IBD Models Can Impact Your Drug Development Program
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
Copyright © 2024 Inotiv. All Rights Reserved.